Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$13.68 USD

13.68
5,608,499

-0.37 (-2.63%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $13.66 -0.02 (-0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Owens & Minor (OMI) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

We expect the strength in demand for Owens & Minor's (OMI) PPEs to have continued through the fourth quarter.

Zacks Equity Research

Ecolab's (ECL) Certified Program to Build Customer Confidence

by Zacks Equity Research

Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.

Zacks Equity Research

Lower Bulk Purchases May Weigh on Medtronic (MDT) Q3 Earnings

by Zacks Equity Research

Medtronic's (MDT) diabetes care, robotics surgery and neuromodulation lines are expected to have performed well in Q3.

Zacks Equity Research

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.

Zacks Equity Research

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.

Zacks Equity Research

OPKO Health (OPK) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

Zacks Equity Research

Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.

Zacks Equity Research

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.

Zacks Equity Research

Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

Zacks Equity Research

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

by Zacks Equity Research

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

Zacks Equity Research

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Zacks Equity Research

Aurora Cannabis (ACB) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Aurora Cannabis' (ACB) sustained consumer cannabis sales are likely to have benefited its performance in the fiscal second quarter.

Zacks Equity Research

Illumina (ILMN) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is likely to have gained during the fourth quarter from the robust performance of sequencing consumable segment.

Zacks Equity Research

Cerner (CERN) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.

Zacks Equity Research

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance by net dialysis and the related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the fourth quarter.

Zacks Equity Research

Align (ALGN) Extends Invisalign G8 Availability Worldwide

by Zacks Equity Research

Align's (ALGN) latest evolution in biomechanics is set to improve treatment predictability for frequently treated case types.

Zacks Equity Research

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Bio-Rad (BIO) Q4 earnings are expected to have benefited from strong sales, particularly within core PCR products, Droplet Digital PCR and Process Media.

Zacks Equity Research

InMode (INMD) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have contributed to the company's Q4 top line.

Zacks Equity Research

Canopy Growth (CGC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in fiscal third quarter.

Zacks Equity Research

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) patient volumes are expected to have increased significantly in the fourth quarter due to pent-up demand.

Zacks Equity Research

STERIS (STE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Within Life Sciences, STERIS (STE) might have registered benefits from pharma customers on growing vaccines, along with a recovery in the Healthcare arm in Q3.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Top Estimates This Earnings Season

by Urmimala Biswas

Strong signs of rebound in base sales volumes make us optimistic about VIVO, XRAY, and PDCO's results.

Zacks Equity Research

What's in Store for IDEXX Laboratories (IDXX) in Q4 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) fourth-quarter top line is likely to have benefited from strength in CAG and LPD businesses.

Zacks Equity Research

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from continued recovery in Clear Aligner shipment volumes in Q4.

Zacks Equity Research

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.